AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was treated in the HEAL-IST™ trial (NCT 05280093). The first patient was treated by Drs. Mark LaMeir...
